Cabergoline treatment results in a prompt and persistent decrease in PRL levels that is dose-dependent. This effect is not confined to patients with bromocriptine intolerance, but is also observed in healthy volunteers and puerperal women. Cabergoline is generally safe during pregnancy, although a thorough risk/benefit evaluation should be done prior to treatment initiation. Nevertheless, it is...